MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)

Consensus Ratings for Eyegate Pharmaceuticals (NASDAQ:EYEG) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.00 (247.49% upside)

Analysts' Ratings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Noble FinancialInitiated CoverageBuy -> Buy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)
Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Eyegate Pharmaceuticals (NASDAQ:EYEG)
DateHeadline
06/30/16 01:07 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Othe -
06/30/16 12:00 PMEyeGate Announces Completion of $3.77 Million Registered Direct Offering - [GlobeNewswire] - WALTHAM, Mass., June 30, 2016-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
06/29/16 06:17 AMStock Volatility in Review: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Engelwood Daily
06/29/16 06:17 AMEyegate Pharmaceuticals Inc (NASDAQ:EYEG)'s Company Shares Decreased 16.44% After High Volatility - Engelwood Daily
06/27/16 03:52 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.50%
06/27/16 03:52 PMBRIEF-Eyegate announces $3.77 mln registered direct offering
06/27/16 01:48 PM9 Biggest Mid-Day Losers For Monday -   Barclays PLC (ADR) (NYSE: BCS) shares dipped 20.6 percent to $7.06 after declining 20.48 percent on Friday. BofA/Merrill Lynch downgraded Barclays from Buy to Neutral, while JP Morgan also downgraded the stock to Neutral. Cobalt International Energy, Inc. (NYSE: CIE) shares fell 17.5 percent to $1.51. Crude oil dropped 2.7 percent to trade at $46.34 a barrel. Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares declined 17.4 percent to $2.52. EyeGate reported a $3.77 million registered direct offering. Lloyds Banking Group PLC (ADR) (NYSE: Full story available on Benzinga.com
06/27/16 08:25 AMEyegate Pharma (EYEG) Enters $3.8M Common Stock Registered Direct Offering - StreetInsider.com
06/27/16 08:25 AMBRIEF-Eyegate Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing - Reuters
06/27/16 07:06 AMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi -
06/27/16 07:04 AM8:04 am Eyegate Pharmaceuticals to sell 441K shares of common stock at $2.25/share and 2776.5 shares of Series A Convertible Preferred Stock to an institutional investor in an ~$3.77 mln direct offering -
06/27/16 07:00 AMEyeGate Announces $3.77 Million Registered Direct Offering - [GlobeNewswire] - WALTHAM, Mass., June 27, 2016-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
06/26/16 03:30 PMEyegate Pharmaceuticals Incorporated (NASDAQ:EYEG) Sellers Covered 22.05% of Their Shorts - Press Telegraph
06/26/16 03:30 PMStrong Sell Calls Recommendations For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) At 0 - Investor Newswire
06/26/16 08:52 AMShare Volatility Check for: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Press Telegraph
06/22/16 03:16 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/19/16 03:42 PMStrong Buy Calls Count For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) At 4 - Investor Newswire
06/14/16 08:48 AMMacular Edema Therapeutic Pipeline Review Report H1 2016
06/12/16 03:52 PMTrend Of Rating Given To Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Investor Newswire
06/03/16 10:06 PMMaxim Group Reiterates “Buy” Rating for Eyegate Pharmaceuticals Inc (EYEG) - Let Me Know About This
06/02/16 04:08 PMEYEGATE PHARMACEUTICALS INC - NEEDHAM, MA--(Marketwired - June 02, 2016) - Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, announced the speaker lineup and final agenda for the 4 th Annual Targeting Ocular Disorders: The Latest Targets, Pathways ...
06/02/16 02:45 PMEYEG: Positive Cataract Surgery Results. Pivotal Study Could Commence By Year-End -
06/01/16 10:12 PMEyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment - WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for ...
05/31/16 04:03 PMEyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Stock Update & Estimates - Stock Tick Tock - Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to post earnings of $-0.36 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/26/16 12:02 PMEyeGate Pharma Announces At The Market Issuance Program - GlobeNewswire (press release) - EyeGate Pharma Announces At The Market Issuance ProgramGlobeNewswire (press release)WALTHAM, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”) announced today that it has entered into an At The Market Issuance ("ATM") Sales Agreement, dated May 24, 2016, with H.C. ...and more »
05/26/16 12:02 PMStocks Swings: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG), Old Republic International Corporation (NYSE:ORI ... - KC Register - Stocks Swings: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG), Old Republic International Corporation (NYSE:ORI ...KC RegisterEyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) announced that it has entered into an At The Market Issuance (“ATM”) Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (the “Sales Agent”), under which the Company may, at its ...
05/26/16 12:02 PMBRIEF-Eyegate Pharmaceuticals to sell up to 1.3 mln shares on NASDAQ Capital Market - Reuters - BRIEF-Eyegate Pharmaceuticals to sell up to 1.3 mln shares on NASDAQ Capital MarketReutersMay 24 Eyegate Pharmaceuticals Inc. * Eyegate Pharmaceuticals Inc says to sell up to a maximum of 1.3 million shares of its common stock through ATM issuances on NASDAQ Capital Market Source text for Eikon: Further company coverage: (Bengaluru ...
05/25/16 05:05 AMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S -
05/24/16 05:00 PMEyeGate Pharma Announces At The Market Issuance Program - [GlobeNewswire] - WALTHAM, Mass., May 24, 2016-- EyeGate Pharmaceuticals, Inc. announced today that it has entered into an At The Market Issuance Sales Agreement, dated May 24, 2016, with H.C. Wainwright& Co., LLC, under ...
05/23/16 04:26 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K/A, Financial Statements and Exhibits -
05/23/16 09:00 AMEYEG: Clinical Timelines On Track. EGP-437 Data in 2H 2016 -
05/13/16 04:25 PMEyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update - [GlobeNewswire] - WALTHAM, Mass., May 13, 2016-- Eyegate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
05/06/16 07:30 AMEyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development - [GlobeNewswire] - WALTHAM, Mass., May 06, 2016-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
04/29/16 03:27 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi -
04/27/16 03:05 PMEyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer - [GlobeNewswire] - WALTHAM, Mass., April 27, 2016-- EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
04/26/16 07:30 AMEyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S - [GlobeNewswire] - WALTHAM, Mass., April 26, 2016-- Eyegate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
04/08/16 07:00 AMEye on the Future; Analyst Report - [Accesswire] - NEW YORK, NY / ACCESSWIRE / April 8, 2016 / EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) is a specialty pharmaceutical company focused on the development and commercialization of therapeutics and drug ...
04/05/16 08:50 AMEYEG: Jade Brings De-Risked, Complementary Pipeline -
03/30/16 03:26 PMEYEGATE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report -
01/26/16 03:23 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers -
01/19/16 07:30 AMEyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis - [GlobeNewswire] - WALTHAM, Mass., Jan. 19, 2016-- Eyegate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases ...
01/16/16 01:50 PMEyegate Pharmaceuticals To Present At The Noble Financial Capital Markets' 12th Annual Investor Conference - WALTHAM, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery ...
11/12/15 05:19 AMEYEGATE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
11/05/15 07:45 AMEyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients - [GlobeNewswire] - WALTHAM, Mass. -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics ...
10/15/15 07:30 AMEyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System - [GlobeNewswire] - Patent to Provide Broad Coverage for EyeGate II(R) Delivery System with Pre-filled Drug Applicator
09/08/15 11:08 AMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
08/05/15 03:17 PMEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Notice of Delisting or Fa -
07/14/15 03:45 PMValeant to Buy Unilens Vision to Boost Contact Lens Business - Analyst Blog -
07/13/15 03:50 PMEyegate-Valeant Team Up for EGP-437; Share Gains for Both - Analyst Blog -
02/10/15 02:18 PMAvenue's Nashville Takeover Kicks Off IPO Sector This Week -
About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EYEG
  • CUSIP:
Key Metrics:
  • Previous Close: $2.59
  • 50 Day Moving Average: $3.18
  • 200 Day Moving Average: $3.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $21.62M
  • Current Quarter EPS Consensus Estimate: $-1.26 EPS
Additional Links:
Eyegate Pharmaceuticals (NASDAQ:EYEG) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha